Abstract In evolution of hypertension's treatment it may no be sufficient to lower blood pressure to achieve beneficial effects in long term outcomes. Several goals of antihypertensive treatment remain unrealized. There is so great interest for new drugs that may protect target organs and improve outcomes. The angiotensin II, the major effector of the renin-angiotensin-aldosterone system, causes a variety of potentially noxious cardiovascular effects which are specially mediated by AT1 subtype receptors. AT1 receptor blockers (losartan, candesartan, irbesartan, valsartan) are available drugs in the angiotensin-II-antagonist class. This paper examine the peculiar features of this new class of drugs.
Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data / Paoletti, V; Di Veroli, C; Pugliese, M; Cammarella, I; Cavina, G; Turchetti, P; Mammarella, Antonio. - In: LA CLINICA TERAPEUTICA. - ISSN 0009-9074. - STAMPA. - 153:(2002), pp. 61-64.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Titolo: | Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data | |
Autori: | ||
Data di pubblicazione: | 2002 | |
Rivista: | ||
Citazione: | Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data / Paoletti, V; Di Veroli, C; Pugliese, M; Cammarella, I; Cavina, G; Turchetti, P; Mammarella, Antonio. - In: LA CLINICA TERAPEUTICA. - ISSN 0009-9074. - STAMPA. - 153:(2002), pp. 61-64. | |
Handle: | http://hdl.handle.net/11573/421747 | |
Appartiene alla tipologia: | 01a Articolo in rivista |